Latest news with #America-led
Yahoo
07-04-2025
- Business
- Yahoo
Trump Exposes Own Kindergarten-Level Understanding of Economics
President Donald Trump said that he hopes to erase the U.S. trade deficit with other countries—but anyone who understands economics knows that wouldn't be a good thing. 'I spoke to a lot of leaders—European, Asian—from all over the world. They are dying to make a deal, but I said, 'We're not gonna have deficits with your country,'' Trump told reporters on board Air Force One Sunday. 'We're not gonna do that, because to me a deficit is a loss. We're gonna have surpluses or at worst we're gonna be breaking even.' A trade deficit isn't a 'loss,' regardless of what Trump thinks. A trade deficit simply means that one country spends more on goods from another country than that country spends on goods from them. Crucially, economists say that having a trade deficit is not an inherently bad thing at all, because the U.S. simply can't and shouldn't make everything. Trump's insistence that the U.S. is being taken for a ride betrayed a fundamental misunderstanding of economics that is built on a dislike of other countries and a desire to be the dealmaker responsible for a new world order. Trump warned that it would be the 'worst' for China. In 2024, the United States had a $295.4 billion trade deficit with China. Trump said that China would need to 'solve their surplus' before he would be willing to make a deal on tariffs. The president predicted that his 'reciprocal tariffs' would raise $1 trillion in the next year and that 'thousands' of companies would relocate manufacturing to the U.S. China announced Friday that it would impose 34 percent tariffs on imports from the U.S. in response to Trump's new 'reciprocal' 34 percent tariff, which was added on top of two rounds of 10 percent tariffs that had been announced last month. Trump's announcement of 'reciprocal tariffs' last week sent the U.S. stock market plummeting to its worst day since 2020, and major financial institutions updated their recession projections for 2025. But Trump merely compared the financial chaos to a sick patient taking their 'medicine.' Trump was widely mocked for his ridiculous plan to eliminate the trade deficit. Tahra Jirari, director of economic analysis at the Chamber of Progress, wrote on X Sunday that 'a trade deficit isn't a 'loss,' it just means we import more than we export. Countries run trade deficits for all kinds of healthy reasons (like strong consumer demand). 'Breaking even' isn't how global trade works.' Zeteo News's editor in chief Mehdi Hasan wrote on X Sunday that Trump was 'an ignoramus the like of which we have not seen in our lifetimes. Wharton must be so embarrassed.' Jonah Goldberg, editor in chief of The Dispatch, wrote in a post on X Monday that 'Trumpers slavishly defend one man unilaterally screwing up the economy and the America-led global order because he's some kind of genius. And it turns out—as was apparent for decades—he just doesn't know what he's talking about.'
Yahoo
18-03-2025
- Business
- Yahoo
Amid deglobalising trade, experts seek AI safeguards for clinical trial supply
The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe conference, as speakers discussed the risks to clinical trial supply in a shifting geopolitical landscape. Representatives from the biopharma industry and governance met through 25–26 February in Barcelona, Spain, for presentations and panel discussions on trial logistics and technological innovation in clinical research. Chief among experts' concerns was the mounting pressure placed on clinical trial supply chains as global trade networks undergo continued regionalisation. The view shared by many was that AI integration will be vital as companies look to safeguard against unforeseen shortages. The conference began with opening remarks from Arnaud Dourlens, head of clinical supply operations at Sanofi. 'Clinical supply is no longer about just delivering drugs', Dourlens stated. 'It's also about delivering agility, resilience, and innovation.' He set the tone for discussions over the next two days by identifying the major trends driving shifting priorities within biopharma research. Strength of supply, he said, has joined underlying science as a prime determinant of trial success. He noted the contribution of pharma to CO₂ emissions as further compounding challenges to robust supply and successful trials. Collaboration and the acceptance of AI will be central in the sector's response to supply challenges, Dourlens said. Directly following Dorulens was Thomas Thoma, head of managed access programmes at Teva Pharmaceuticals. Thoma spoke about the newly empowered European Shortages Monitoring Platform (ESMP) of the EU to combat drug shortages in the continent. Since 2 February, companies and EU member states must report critical medicine stocks and shortages via this platform to enable drug sharing between countries as part of the MSSG [Executive Steering Group on Shortages and Safety of Medicinal Products] solidarity mechanism. In addition to addressing concerns within Europe, presenters spoke on the broader trend of deglobalisation in biopharma. GlobalData analyst Carolina Pinto described to attendees the geopolitical drivers of this trend. Due to insular US foreign policy, Pinto said a 'bifurcation' of global trade between an America-led West and China-led East has taken place. 'Since 2020, the disruption [to supply chains] has been unprecedented,' she stated, noting a shift among companies from responsive 'just-in-time' supply models to 'just-in-case' ones based on maintaining inventories to safeguard against unforeseen shortage. GlobalData is the parent company of Pharmaceutical Technology. This new paradigm of pre-emptive risk management should be centred on AI-enabled data analysis, according to Colin Shelton, clinical supply chain group director at GSK. Shelton emphasised the need for quick action and efficient communication for companies to adapt to growing uncertainty in trial supply. Others such as Marcel Walraven, supply chain specialist at clinical courier Biocair, saw opportunity in fragmented trade networks. For companies like Biocair, Walraven anticipated a surge in demand for increasingly complex international transport of clinical trial materials. The conference's second day began with a presentation from Andreas Schwinn, senior qualified person for investigational medicinal products at Roche. Schwinn said an overhaul in the EU Clinical Trial Regulations is set to simplify approvals in what he described as 'probably the most important regulatory development within the past decades for clinical trials'. Harmonised processes pave the way for speedier approval and eased shortages, Schwinn said. Later in the day, a panel discussion on how private companies might harmonise their research and supply was moderated by Fernanda Teles, head of global clinical logistics at DHL Supply Chain. It is crucial to evaluate performance metrics more accurately to this end, according to Pierre-Gaultier Delheid, head of clinical supply partnering at UCB. Conversely, increased partnership was seen as most key to harmonisation by Aiden Smith, director of global business development at DHL. Contributing to discussion on AI throughout the conference was Chandrakumar Pillai, an enterprise architect with the European Commission. Pillai delved into the transformative potential of AI to maximise trial enrolment through medical data analysis and optimise supply management by forecasting demand. The conference concluded with a series of problem-solving roundtable discussions. This included a session on the real-world use of machine learning tools to optimise supply management by Gianpiero Lorusso, an independent cold chain expert. Lorusso used the example of Genlots, an AI-powered enterprise resource planner (ERP) based in Morges, Switzerland, to demonstrate how such technologies can minimise the cost, emissions, and delivery times involved in clinical trial supply. "Amid deglobalising trade, experts seek AI safeguards for clinical trial supply" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
11-03-2025
- Business
- Yahoo
Amid deglobalising trade, experts seek AI safeguards for clinical trial supply
The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe conference, as speakers discussed the risks to clinical trial supply in a shifting geopolitical landscape. Representatives from the biopharma industry and governance met through 25–26 February in Barcelona, Spain, for presentations and panel discussions on trial logistics and technological innovation in clinical research. Chief among experts' concerns was the mounting pressure placed on clinical trial supply chains as global trade networks undergo continued regionalisation. The view shared by many was that AI integration will be vital as companies look to safeguard against unforeseen shortages. The conference began with opening remarks from Arnaud Dourlens, head of clinical supply operations at Sanofi. 'Clinical supply is no longer about just delivering drugs', Dourlens stated. 'It's also about delivering agility, resilience, and innovation.' He set the tone for discussions over the next two days by identifying the major trends driving shifting priorities within biopharma research. Strength of supply, he said, has joined underlying science as a prime determinant of trial success. He noted the contribution of pharma to CO₂ emissions as further compounding challenges to robust supply and successful trials. Collaboration and the acceptance of AI will be central in the sector's response to supply challenges, Dourlens said. Directly following Dorulens was Thomas Thoma, head of managed access programmes at Teva Pharmaceuticals. Thoma spoke about the newly empowered European Shortages Monitoring Platform (ESMP) of the EU to combat drug shortages in the continent. Since 2 February, companies and EU member states must report critical medicine stocks and shortages via this platform to enable drug sharing between countries as part of the MSSG [Executive Steering Group on Shortages and Safety of Medicinal Products] solidarity mechanism. In addition to addressing concerns within Europe, presenters spoke on the broader trend of deglobalisation in biopharma. GlobalData analyst Carolina Pinto described to attendees the geopolitical drivers of this trend. Due to insular US foreign policy, Pinto said a 'bifurcation' of global trade between an America-led West and China-led East has taken place. 'Since 2020, the disruption [to supply chains] has been unprecedented,' she stated, noting a shift among companies from responsive 'just-in-time' supply models to 'just-in-case' ones based on maintaining inventories to safeguard against unforeseen shortage. GlobalData is the parent company of Pharmaceutical Technology. This new paradigm of pre-emptive risk management should be centred on AI-enabled data analysis, according to Colin Shelton, clinical supply chain group director at GSK. Shelton emphasised the need for quick action and efficient communication for companies to adapt to growing uncertainty in trial supply. Others such as Marcel Walraven, supply chain specialist at clinical courier Biocair, saw opportunity in fragmented trade networks. For companies like Biocair, Walraven anticipated a surge in demand for increasingly complex international transport of clinical trial materials. The conference's second day began with a presentation from Andreas Schwinn, senior qualified person for investigational medicinal products at Roche. Schwinn said an overhaul in the EU Clinical Trial Regulations is set to simplify approvals in what he described as 'probably the most important regulatory development within the past decades for clinical trials'. Harmonised processes pave the way for speedier approval and eased shortages, Schwinn said. Later in the day, a panel discussion on how private companies might harmonise their research and supply was moderated by Fernanda Teles, head of global clinical logistics at DHL Supply Chain. It is crucial to evaluate performance metrics more accurately to this end, according to Pierre-Gaultier Delheid, head of clinical supply partnering at UCB. Conversely, increased partnership was seen as most key to harmonisation by Aiden Smith, director of global business development at DHL. Contributing to discussion on AI throughout the conference was Chandrakumar Pillai, an enterprise architect with the European Commission. Pillai delved into the transformative potential of AI to maximise trial enrolment through medical data analysis and optimise supply management by forecasting demand. The conference concluded with a series of problem-solving roundtable discussions. This included a session on the real-world use of machine learning tools to optimise supply management by Gianpiero Lorusso, an independent cold chain expert. Lorusso used the example of Genlots, an AI-powered enterprise resource planner (ERP) based in Morges, Switzerland, to demonstrate how such technologies can minimise the cost, emissions, and delivery times involved in clinical trial supply. "Amid deglobalising trade, experts seek AI safeguards for clinical trial supply" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
07-03-2025
- Politics
- Yahoo
Trump threatens sanctions on Russia, demands peace after major hits in Ukraine
President Donald Trump threatened to impose "large scale" sanctions against Russia after the country carried out a massive attack on Ukraine's energy infrastructure. In a post on Truth Social, President Trump said he was "strongly considering" sanctions and tariffs "until a ceasefire and final settlement agreement on peace is reached." National Economic Council Director Kevin Hassett told reporters that Trump is ready to use carrots or sticks" to bring both Russia and Ukraine to the table. When asked by Fox News Channel Senior White House Correspondent Jacqui Heinrich for more details on what could be sanctioned, Hassett simply said there are "a heck of a lot of things." In the overnight attack, Russia reportedly fired 67 missiles and 194 drones in an overnight attack that hit Ukraine's energy and gas infrastructure, Reuters reported, citing Ukraine's air force. According to reports, at least 10 people were injured in Russia's attack, including a child. Zelenskyy Confirms Ukraine Will Attend America-led Peace Talks Days After Oval Office Clash "Russia continues its energy terror," Ukrainian Energy Minister Herman Halushchenko wrote on Facebook. "Again energy and gas infrastructure in various regions of Ukraine has come under massive missile and drone fire." Russia has attacked Ukraine's energy infrastructure multiple times throughout the three-year war. In April 2024, Russia destroyed one of Ukraine's largest power plants, and in December 2024, Russia pummeled Ukraine's power grid. Read On The Fox News App President Trump also included a message to both Ukraine and Russia in his Truth Social post: "Get to the table right now, before it is too late." Secretary Of State Rubio Vows Diplomacy Attempts Will Continue In Effort To End Russia's War In Ukraine Friday's attack seemed to be in response to Ukrainian President Volodymyr Zelenskyy confirming that his team would participate in peace talks with the U.S. in Saudi Arabia next week. While Zelenskyy himself will not be at the meeting, his team will sit with their American counterparts to discuss ending the war. In his announcement of Ukraine's participation in the talks, Zelenskyy said his country is "most interested in peace." The issue of peace caused friction between Trump and Zelenskyy, after the president said his Ukrainian counterpart was "not ready for peace" following their Oval Office spat. "He disrespected the United States of America in its cherished Oval Office. He can come back when he is ready for peace," Trump wrote on Truth Social last week after the heated meeting. However, things seemed to have smoothed over between the two leaders, with Trump reading a letter from Zelenskyy during his address to a joint session of Congress. Trump said he appreciated Zelenskyy's letter and that he wants to see the "savage conflict" end. Fox News Channel's Jacqui Heinrich contributed to this article source: Trump threatens sanctions on Russia, demands peace after major hits in Ukraine
Yahoo
29-01-2025
- Politics
- Yahoo
Former Obama administration adviser flew to Britain to rape nine-year-old girl
A former policy adviser to Barack Obama's administration flew to Britain planning to rape a nine-year-old child. Rahamim 'Rami' Shy, 47, an investment banker who helped co-ordinate the US government's counter-terror response, travelled from New York to Bedfordshire to meet an English schoolgirl. He spent more than a month planning the trip and had packed his suitcases with cuddly toys and condoms, Luton Crown Court heard. On an online forum and messaging apps, Shy described the 'unspeakable acts' he was planning in graphic detail to someone he believed to be the girl's grandmother. But the grandmother, using the name Debbie, was in fact an online decoy created by an undercover officer from Bedfordshire Police. In his messages, Shy described the girl as a 'tad late' in starting sexual activity at the age of nine, and said that it was an 'honour' to be considered 'her first', the court heard. He flew to Gatwick on Feb 23 last year then drove to Bedford to meet the undercover officer, and was promptly arrested. His lawyers tried to claim that as he was in the US at the time of the messaging, he was jurisdictionally exempt from prosecution in the UK. But the Crown Prosecution Service successfully argued that English courts have jurisdiction to try offences committed abroad that are intended to result in criminal offences in England. During the trial, the court heard Shy, after arriving in Britain, tried to delete the 'depraved messages' he had sent. Other messages retrieved from his phone revealed he had discussed his sexual interest in children with others. A cache of indecent images of children were discovered on his phone by police. Officers also found several cuddly toys and condoms within Shy's luggage after his arrest. The prosecution argued the items demonstrated 'a clear intent to win the child over' before abusing her. On Wednesday, Shy was jailed for 11 years and six months after being found guilty of arranging the commission of a child sex offence – namely rape – and possessing indecent photographs of a child. Shy was previously employed at banking group Citi, and had worked in a senior role at the US treasury department from 2008 to 2014, advising officials on countering the financing of terrorism and assisting foreign governments to impose sanctions on hostile regimes, the Daily Mail reported at the time of his arrest. A spokesman from Citi said that Shy was no longer an employee following his arrest. Shy was also deployed to Afghanistan to provide expertise to the Nato-led International Security Assistance Force (ISAF), set up to maintain stability following the America-led invasion of the country. According to a LinkedIn page, he provided ISAF with counter-terrorist finance expertise, and went on to present the US's strategy on Afghanistan to a congressional hearing in 2010. Lorraine Telford, of the CPS, said: 'Rahamim Shy is a predator who was fully prepared to commit unspeakable acts against a child for his own sexual gratification. 'It was clear from his explicit conversations and items he brought to England that he had only one intention, to commit rape against what he knew was a vulnerable child. 'The fact the child in this case did not exist makes no difference, and it is a credit to the police operation and subsequent prosecution that Shy will no longer pose an immediate threat. 'All children have the right to feel safe and protected, and I hope this conviction sends a clear message that the CPS, working closely alongside law enforcement, will relentlessly pursue justice and prosecute those who seek to sexually exploit children.'
